CORE--MULTIPLEXED GENE ANALYSIS

$0P30FY2001CANIH

Washington University, Saint Louis MO

Investigators

Linked publications & trials

Paper 39672808 Paper 39661664 Paper 39606421 Paper 39605713 Paper 39605615 Paper 39554000 Paper 39546604 Paper 39538331 Paper 39513366 Paper 39484596 Paper 39483883 Paper 39471823 Paper 39463952 Paper 39416092 Paper 39400554 Paper 39385703 Paper 39367170 Paper 39314156 Paper 39292011 Paper 39282008 Paper 39229002 Paper 39215060 Paper 39186784 Paper 39178114 Paper 39164479 Paper 39149385 Paper 39117799 Paper 39048822 Paper 39047765 Paper 39046877 Paper 39042188 Paper 39023130 Paper 38979159 Paper 38956087 Paper 38948690 Paper 38942017 Paper 38941871 Paper 38915487 Paper 38895266 Paper 38861030 Paper 38857377 Paper 38853836 Paper 38848040 Paper 38829200 Paper 38821054 Paper 38816363 Paper 38809511 Paper 38805302 Paper 38768391 Paper 38753748 Paper 38748998 Paper 38737793 Paper 38733994 Paper 38720117 Paper 38717161 Paper 38713894 Paper 38712231 Paper 38712036 Paper 38710222 Paper 38683120 Paper 38659818 Paper 38648485 Paper 38636518 Paper 38607967 Paper 38603763 Paper 38602479 Paper 38593045 Paper 38584584 Paper 38565883 Paper 38563906 Paper 38562794 Paper 38558990 Paper 38551064 Paper 38481947 Paper 38480650 Paper 38477709 Paper 38452172 Paper 38443823 Paper 38422918 Paper 38421682 Paper 38405731 Paper 38388857 Paper 38385175 Paper 38365827 Paper 38334649 Paper 38334461 Paper 38308315 Paper 38299059 Paper 38295174 Paper 38294237 Paper 38280549 Paper 38278365 Paper 38261979 Paper 38234814 Paper 38234811 Paper 38230294 Paper 38212428 Paper 38201640 Paper 38178622 Paper 38174998

Abstract

The Multiplexed Gene Analysis Core (MGAC) allows Cancer Center members access to emerging technologies for high-throughput often are associated with considerable infrastructure, cold with considerable infrastructure, cost, quality control and/or complexity, making them difficult to establish in individual laboratories. In addition to providing technical resources for both basic and translational cancer research, the Core also will facilitate integration of the large data sets often obtained from utilizing these technologies into the investigators' research program. Currently, the Core has invested in commercially produced oligonucleotide array technologies (Affymetrix GeneChips), directed at gene expression profiling. The GeneChip Facility already has produced expression profile data for more than 30 different cancer-related projects being conducted by funded Cancer Center members. A centralized resource that will allow investigators to collect, organize, and analyze large gene expression data sets is now currently in development. In the future, other technologies for mutation scanning and proteomic analysis will be developed and supported.

View original record on NIH RePORTER →